Literature DB >> 19455567

Cardiac amyloidosis treated with an implantable cardioverter defibrillator and subcutaneous array lead system: report of a case and literature review.

Abhijeet Dhoble1, Atul Khasnis, Adesuwa Olomu, Ranjan Thakur.   

Abstract

BACKGROUND: Preventing ventricular arrhythmias in patients with cardiac amyloidosis is challenging since the amyloid protein deposition in the myocardium may interfere with the normal cardiac electric excitation. Most of these patients succumb to either progressive congestive heart failure, or sudden cardiac death (SCD). Implantable cardioverter defibrillator (ICD) offers a near sure means of preventing SCD. HYPOTHESIS: Myocardial infiltration with amyloid results in elevated defibrillation threshold (DFT). Intra-operative strategies may fail to lower DFT during implantation.
METHODS: We present a case of a 64-year-old female who had cardiac amyloidosis, and was successfully treated with an ICD and a subcutaneous array lead system.
CONCLUSION: A subcutaneous array lead system is useful in reducing the DFT, and can terminate ventricular tachycardia or fibrillation by allowing more energy delivery and efficient defibrillation.

Entities:  

Mesh:

Year:  2009        PMID: 19455567      PMCID: PMC6653454          DOI: 10.1002/clc.20389

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  9 in total

1.  P-wave dispersion in systemic AA amyloidosis of familial Mediterranean fever.

Authors:  Udi Nussinovitch; Avi Livneh; Moshe Nussinovitch; Benjamin Volovitz; Ilan Ben-Zvi; Merav Lidar; Naomi Nussinovitch
Journal:  Clin Rheumatol       Date:  2011-04-12       Impact factor: 2.980

Review 2.  Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.

Authors:  Adam Castaño; Brian M Drachman; Daniel Judge; Mathew S Maurer
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

Review 3.  Natural history and therapy of AL cardiac amyloidosis.

Authors:  Martha Grogan; Angela Dispenzieri
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

Review 4.  Clinical management of amyloid cardiomyopathy.

Authors:  Morris M Kim; Clinton M Kolseth; Dayna Carlson; Ahmad Masri
Journal:  Heart Fail Rev       Date:  2021-09-01       Impact factor: 4.654

5.  Trends, burden, and impact of arrhythmia on cardiac amyloid patients: A 16-year nationwide study from 1999 to 2014.

Authors:  Ameesh Isath; Ashish Correa; Gregory P Siroky; Stuthi Perimbeti; Selma Mohammed; C Anwar A Chahal; Deepak Padmanabhan; Davendra Mehta
Journal:  J Arrhythm       Date:  2020-06-11

6.  Focal monomorphic ventricular tachycardia as the first manifestation of amyloid cardiomyopathy.

Authors:  Srikanth Seethala; Sandeep Jain; N Paul Ohori; Sara Monaco; Joan Lacomis; Frederick Crock; Jan Nemec
Journal:  Indian Pacing Electrophysiol J       Date:  2010-03-05

7.  Cardiac amyloidosis presenting with prolonged QT interval and recurrent polymorphic ventricular tachycardia.

Authors:  Nisha A Gilotra; Grant V Chow; Oscar H Cingolani
Journal:  Tex Heart Inst J       Date:  2013

8.  Modes of death in patients with heart failure and preserved ejection fraction.

Authors:  Stefan Aschauer; Caroline Zotter-Tufaro; Franz Duca; Andreas Kammerlander; Daniel Dalos; Julia Mascherbauer; Diana Bonderman
Journal:  Int J Cardiol       Date:  2016-11-18       Impact factor: 4.164

9.  Updates in cardiac amyloidosis: a review.

Authors:  Sanjay M Banypersad; James C Moon; Carol Whelan; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  J Am Heart Assoc       Date:  2012-04-24       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.